Up to 40 minutes a day can be spent on cleaning OPEP devices for those at highest risk of infection. Furthermore, these reusable and expensive devices are not compatible with single patient use hospital applications for acute respiratory illnesses or with infection control guidelines. Our patent protected mechanism allows us to deliver safe, effective airway clearance to patients with Cystic Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), or bronchiectasis in a disposable device. In comparison to other devices, Solopep delivers the same mechanical performance but in the smallest form factor of any product already on the market. This affords patients greater discretion to carry out airway clearance whenever and wherever it is required. In two HPRA approved studies of patients with cystic fibrosis and COPD, the results of which were recently presented at the European Cystic Fibrosis Society conference, Solopep was shown to be as effective at maintaining pulmonary function as the current market leader. Participants replaced their current device with Solopep for one month, with 100% of patients preferring Solopep to their current device. Ideally suited to the acute or home setting, Solopep is a cost effective and safe way to deliver airway clearance therapy to patients whether it’s for a day, a month, or a lifetime.
© www.solopep.com 2019